Aveanna healthcare holdings sees $2,518 stock sale by J.H. Whitney equity partners

Published 27/03/2025, 00:26
Aveanna healthcare holdings sees $2,518 stock sale by J.H. Whitney equity partners

J.H. Whitney Equity Partners VII, LLC, a significant shareholder in Aveanna Healthcare Holdings , Inc. (NASDAQ:AVAH), has reported a sale of shares totaling $2,518. The transactions, disclosed in a recent SEC filing, occurred over two days, March 24 and March 25, 2025. The shares were sold at prices ranging from $5.63 to $5.64. The sale comes amid AVAH’s impressive market performance, with the stock delivering a 129.91% return over the past year and trading near $5.38, according to InvestingPro data.

The sales involved multiple transactions by entities associated with J.H. Whitney, including J.H. Whitney VII, L.P., PSA Healthcare Investment Holding LLC, and PSA Iliad Holdings LLC. Following these transactions, the reported holdings of these entities in Aveanna Healthcare have been adjusted accordingly. With a market capitalization of $1.05 billion and significant price volatility, investors can access comprehensive analysis and 7 additional key insights through InvestingPro’s detailed research reports.

In other recent news, Aveanna Healthcare Holdings Inc. reported strong financial results for the fourth quarter of 2024, with earnings per share reaching $0.05, surpassing the expected loss of $0.003. The company also exceeded revenue expectations, reporting $519.9 million against a forecast of $499.07 million. These results reflect Aveanna’s effective operational strategies and growth across all divisions, particularly in Private Duty Services, which saw a 10.1% increase. Additionally, Moody’s has affirmed Aveanna’s Caa1 rating and revised its outlook to positive, citing improvements in business performance and leverage reduction. The company’s liquidity remains adequate, supported by $84 million in cash and a revolving credit facility with approximately $138 million available. UBS, however, maintains a Sell rating on Aveanna’s shares, despite raising the price target to $4.50 from $3.20. This reflects ongoing concerns despite recent management changes and operational improvements. These developments indicate Aveanna’s strategic focus on expanding its payer agreements and enhancing service offerings, positioning the company for continued growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.